These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38639698)
1. Impact of Insurance Status and Region on Angiotensin Receptor-Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations. Davogustto G; Wells QS; Harrell FE; Greene SJ; Roden DM; Stevenson LW JACC Heart Fail; 2024 May; 12(5):864-875. PubMed ID: 38639698 [TBL] [Abstract][Full Text] [Related]
2. Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. Luo N; Lippmann SJ; Mentz RJ; Greiner MA; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Peterson PN; Fonarow GC; O'Brien EC J Am Heart Assoc; 2019 Feb; 8(3):e010484. PubMed ID: 30712431 [TBL] [Abstract][Full Text] [Related]
3. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417 [TBL] [Abstract][Full Text] [Related]
4. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
5. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679 [TBL] [Abstract][Full Text] [Related]
6. Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction. Tran JS; Loveland MG; Alamer A; Piña IL; Sweitzer NK Circ Heart Fail; 2022 Nov; 15(11):e009395. PubMed ID: 36378759 [TBL] [Abstract][Full Text] [Related]
7. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction. Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734 [TBL] [Abstract][Full Text] [Related]
8. Risk of Acute Kidney Injury Among Older Adults With Heart Failure and With Reduced Ejection Fraction Treated With Angiotensin-Neprilysin Inhibitor vs Renin-Angiotensin System Inhibitor in Routine Clinical Care. Bhatt AS; Vaduganathan M; Zhuo M; Fu EL; Solomon SD; Desai RJ J Card Fail; 2023 Feb; 29(2):138-146. PubMed ID: 36191759 [TBL] [Abstract][Full Text] [Related]
9. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697 [TBL] [Abstract][Full Text] [Related]
10. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure. Greene SJ; Ayodele I; Pierce JB; Khan MS; Lewsey SC; Yancy CW; Alhanti B; Van Spall HGC; Allen LA; Fonarow GC JACC Heart Fail; 2024 Aug; 12(8):1365-1377. PubMed ID: 38597866 [TBL] [Abstract][Full Text] [Related]
12. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107 [TBL] [Abstract][Full Text] [Related]
13. Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. Luo N; Ballew NG; O'Brien EC; Greiner MA; Peterson PN; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Mentz RJ; Fonarow GC Am Heart J; 2018 Jun; 200():134-140. PubMed ID: 29898842 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR). Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan. Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Desai RJ; Patorno E; Vaduganathan M; Mahesri M; Chin K; Levin R; Solomon SD; Schneeweiss S Heart; 2021 Sep; 107(17):1407-1416. PubMed ID: 34088766 [TBL] [Abstract][Full Text] [Related]
17. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors. Pierce JB; Blumer V; Choi S; Hardy NC; Greiner MA; Carnicelli AP; Shen X; Lippmann SJ; Peterson PN; Allen LA; Fonarow GC; Mentz RJ; Greene SJ; O'Brien EC Am J Cardiol; 2023 Oct; 204():151-158. PubMed ID: 37544137 [TBL] [Abstract][Full Text] [Related]
18. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40. Zhao M; Xin Y; Li J; Cao X; Liu X Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852 [TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure. Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. Książczyk M; Lelonek M Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]